GSK, Cambridge researchers join hands in gene project

In an innovative new research pact, scientists from the Medical Research Council in Cambridge and GlaxoSmithKline will collaborate on new work to identify the genetic causes of diseases. Under the deal, both of the groups will invest 1 million sterling into the research as they explore new disease targets and biomarkers. The pact also allows molecular scientists to explore each other's databases.

"It's a question of scale. We need to increase the scale of the studies and in the case of the work with GSK, it's bringing together larger numbers of cohorts," Professor Nick Wareham at the MRC Epidemiology Unit in Cambridge tells Business Weekly.

- check out the article from Business Weekly

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.